Moody's could cut Hospira

Moody's Investors Service said it placed Hospira, Inc.'s Baa3 long-term debt rating on review for downgrade.

This action follows the FDA's new warning letter related to an inspection of the company's device operations at its Lake Forest site and the company's release of its new medical device strategy and revised guidance for fiscal 2013 earlier this month, the agency said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.